| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.5 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.5 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.5 |